USRE43423E1 - Crude extracts from Andrographis paniculata - Google Patents
Crude extracts from Andrographis paniculata Download PDFInfo
- Publication number
- USRE43423E1 USRE43423E1 US13/189,444 US201113189444A USRE43423E US RE43423 E1 USRE43423 E1 US RE43423E1 US 201113189444 A US201113189444 A US 201113189444A US RE43423 E USRE43423 E US RE43423E
- Authority
- US
- United States
- Prior art keywords
- weight
- andrographolide
- extract
- deoxy
- dehydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Definitions
- Tumor Necrosis Factor alpha a mononuclear cytokine, is predominantly produced by monocytes and macrophages. It possesses various biological activities: (1) killing cancer cells or inhibiting growth of cancer cells, (2) enhancing phagocytosis of neutrophilic granulocyte, (3) killing infectious pathogens, and (4) increasing expression of adhesion molecules on vascular endothelial cells during inflammatory responses.
- TNF- ⁇ disorders related to expression of TNF- ⁇ include, but are not limited to, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, spondyloarthropathies, inflammatory bowel disease (including Crohn's disease and ulcerative colitis), chronic heart failure, systemic lupus erythematosus, scleroderma, sarcoidosis, polymyositis/dermatomyositis, psoriasis, multiple myeloma, myelodysplastic syndrome, acute myelogenous leukemia, Parkinson's disease, AIDS dementia complex, Alzheimer's disease, depression, sepsis, pyoderma gangrenosum, hematosepsis, septic shock, Behcet's syndrome, graft-versus-host disease, uveitis, Wegener's granulomatosis, Sjogren's syndrome, chronic obstructive pulmonary disease
- Interleukin-1 beta IL-1 ⁇
- IL-1 ⁇ Interleukin-1 beta
- monocytes hematosepsis
- monocytes hematosepsis
- dendritic cells mediates a wide range of immune and inflammatory responses.
- IL-1 ⁇ Interleukin-1 beta
- disorders such as rheumatoid arthritis, hematosepsis, periodontal disease, chronic heart failure,
- This invention is based on a surprising discovery that an extract of Andrographis paniculata inhibits expression of both TNF ⁇ and IL-1 ⁇ .
- the extract obtained from the aerial part of Andrographis paniculata, contains andrographolide, 14-deoxy-andrographolide, 14-deoxy-11,12-dehydrogen-andrographolide, and neoandrographolide.
- the extract contains 2-20% by weight andrographolide, 1-6% by weight 14-deoxy-andrographolide, 1-12% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 1-5% by weight neoandrographolide.
- the extract contains 3-8% by weight andrographolide, 3-5% by weight 14-deoxy-andrographolide, 7-9% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 2-4% by weight neoandrographolide. It is particularly preferred that the extract contain 4.2% by weight andrographolide, 4.4% by weight 14-deoxy-andrographolide, 8% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 2.1% by weight neoandrographolide.
- One aspect of this invention relates to a method of inhibiting expression of TNF ⁇ or IL-1 ⁇ in a subject.
- the method includes administering to the subject an effective amount of the above-described extract.
- Another aspect of this invention relates to a method of treating a disorder related to TNF ⁇ or IL-1 ⁇ , i.e., inflammatory bowel disease (including Crohn's disease and ulcerative colitis), chronic heart failure, diabetes mellitus, systemic lupus erythematosus, polymyositis/dennatomyositis, psoriasis, acute myelogenous leukemia, AIDS dementia complex, hematosepsis, septic shock, graft-versus-host disease, uveitis, asthma, acute pancreatitis, or periodontal disease.
- the method includes administering to a subject in need of the treatment an effective amount of the above-described extract.
- compositions containing the extract of this invention described above for use in treating TNF ⁇ related disorders and IL-1 ⁇ related disorders as well as the use of such a composition for the manufacture of a medicament for treating these disorders.
- This invention includes methods of inhibiting expression of TNF ⁇ or IL- ⁇ , treating a TNF ⁇ related-disorder, and treating an IL- ⁇ -realted disorder by administering to a subject in need thereof an effective amount of the above-described extract.
- an effective amount refers to the amount of the extract which is required to confer one of the above-described effects in the subject. Effective amounts may vary, as recognized by those skilled in the art, depending on route of administration, excipient usage, and the possibility of co-usage with other agents.
- treating refers to administering the extract to a subject that has a TNF ⁇ related disorder or an IL- ⁇ related disorder, or has a symptom of the disorder, or has a predisposition toward the disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the disorder, the symptoms of the disorder, or the predisposition toward the disorder.
- an extract for use in this invention one can immerse the aerial part of Andrographis paniculata in one or more suitable solvents, e.g., ethanol, methanol, and acetone; separate the liquid from the solid residue; and concentrate the liquid.
- suitable solvents e.g., ethanol, methanol, and acetone
- the extract thus obtained may be further processed. For example, one can remove impurities or modify the ratio of the components by chromatography.
- parenteral includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
- An oral composition can be any orally acceptable dosage form including, but not limited to, tablets, capsules, emulsions and aqueous suspensions, dispersions and solutions.
- Commonly used carriers for tablets include lactose and corn starch.
- Lubricating agents, such as magnesium stearate, are also typically added to tablets.
- useful diluents include lactose and dried corn starch.
- a sterile injectable composition e.g., aqueous or oleaginous suspension
- a sterile injectable composition can be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents.
- the sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
- suitable vehicles and solvents that can be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium (e.g., synthetic mono- or di-glycerides).
- Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
- These oil solutions or suspensions can also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents.
- An inhalation composition can be prepared according to techniques well known in the art of pharmaceutical formulation and can be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
- a topical composition can be formulated in form of oil, cream, lotion, ointment and the like.
- suitable carriers for the composition include vegetable or mineral oils, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohols (greater than C12).
- the preferred carriers are those in which the active ingredient is soluble.
- Emulsifiers, stabilizers, humectants and antioxidants may also be included as well as agents imparting color or fragrance, if desired.
- transdermal penetration enhancers may be employed in these topical formulations. Examples of such enhancers can be found in U.S. Pat. Nos. 3,989,816 and 4,444,762.
- Creams are preferably formulated from a mixture of mineral oil, self-emulsifying beeswax and water in which mixture the active ingredient, dissolved in a small amount of an oil, such as almond oil, is admixed.
- An example of such a cream is one which includes about 40 parts water, about 20 parts beeswax, about 40 parts mineral oil and about 1 part almond oil.
- Ointments may he formulated by mixing a solution of the active ingredient in a vegetable oil, such as almond oil, with warm soft paraffin and allowing the mixture to cool.
- An example of such an ointment is one which includes about 30% almond and about 70% white soft paraffin by weight.
- a carrier in a pharmaceutical composition must be “acceptable” in the sense of being compatible with the active ingredient of the formulation (and preferably, capable of stabilizing it) and not deleterious to the subject to be treated.
- solubilizing agents such as cyclodextrins (which form specific, more soluble complexes with one or more of active compounds of the extract), can be utilized as pharmaceutical excipients for delivery of the active compounds.
- examples of other carriers include colloidal silicon dioxide, magnesium stearate, cellulose, sodium lauryl sulfate, and D&C Yellow #10.
- a suitable in vitro assay can be used to preliminarily evaluate the efficacy of the above-described extract in inhibiting expression of TNF ⁇ or IL-10 expression.
- the extract can further be examined for its efficacy in treating a TNF ⁇ related disorder or an IL-1 ⁇ related disorder by in vivo assays.
- the extract can be administered to an animal (e.g., a mouse model) having a TNF ⁇ or IL-1 ⁇ related disorder and its therapeutic effects are then accessed. Based on the results, an appropriate dosage range and administration route can also be determined.
- PBMC Peripheral blood monocytes
- TNF ⁇ and IL-1 ⁇ were measured using the TNF ⁇ ELISA (Enzyme Linked Immunosorbent Assay) Kit and IL1- ⁇ ELISA Kit (Jingmei Bioengineer Technology).
- the inhibition ratio was calculated as follows:
- Inhibition Ratio (%) ( 1 - C extract - C Control C LPS - C Control ) ⁇ 100 where C extract is the concentration of TNF ⁇ or IL-1 ⁇ in PBMC cells treated with the extract and LPS, C LPS is the concentration of TNF ⁇ or IL-1 ⁇ in PBMC cells treated with LPS and dexamethason, and C Control is the concentration of TNF ⁇ or IL-1 ⁇ in PBMC cells without being treated with LPS or the extract.
- IBD inflammatory bowel disease
- mice (18-24 g) were anaesthetized with 1% pentobarbital sodium at 0.05 mg/10 g.
- pentobarbital sodium 1% pentobarbital sodium at 0.05 mg/10 g.
- TNBS 2,4,6-trinitrobenzenesulfonic acid
- Blank control mice only received 0.1 ml of 50% ethanol.
- the mice were treated with the extract of Andrographis paniculata 24 hours and 2 hours prior to the TNBS administration and daily for 5 days after the administration.
- mice The body weight of each mouse was monitored every day before and after the TNBS administration. The mice were sacrificed 24 hours after the last administration of the extract. Colons were removed and weighed. Furthermore, the colon weight to body weight ratio was calculated and adhesion between colon and other organs was also monitored.
- mice were treated with the extract of Andrographis paniculata (500 mg/kg/day) prior to the induction of IBD they had a reduced overall mortality rate, less severe wasting syndrome, a lower colon weight to body weight ratio, and a lower IBD score.
- the bowel wall was sleek and was not adhesive with surrounding tissues.
- rats treated with the Andrographis paniculata extract had a reduced overall mortality rate, less severe wasting syndrome, a lower colon weight to body weight ratio, and a lower IBD score, compared with those not treated with the extract.
Abstract
Description
where Cextract is the concentration of TNFα or IL-1β in PBMC cells treated with the extract and LPS, CLPS is the concentration of TNFα or IL-1β in PBMC cells treated with LPS and dexamethason, and CControl is the concentration of TNFα or IL-1β in PBMC cells without being treated with LPS or the extract.
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/189,444 USRE43423E1 (en) | 2004-04-28 | 2011-07-22 | Crude extracts from Andrographis paniculata |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56647704P | 2004-04-28 | 2004-04-28 | |
US11/116,678 US7341748B2 (en) | 2004-04-28 | 2005-04-27 | Crude extracts from Andrographis paniculata |
US12/717,260 USRE42718E1 (en) | 2004-04-28 | 2010-03-04 | Crude extracts from andrographis paniculata |
US13/189,444 USRE43423E1 (en) | 2004-04-28 | 2011-07-22 | Crude extracts from Andrographis paniculata |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/116,678 Reissue US7341748B2 (en) | 2004-04-28 | 2005-04-27 | Crude extracts from Andrographis paniculata |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE43423E1 true USRE43423E1 (en) | 2012-05-29 |
Family
ID=35242143
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/116,678 Ceased US7341748B2 (en) | 2004-04-28 | 2005-04-27 | Crude extracts from Andrographis paniculata |
US12/717,260 Active USRE42718E1 (en) | 2004-04-28 | 2010-03-04 | Crude extracts from andrographis paniculata |
US13/189,444 Active USRE43423E1 (en) | 2004-04-28 | 2011-07-22 | Crude extracts from Andrographis paniculata |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/116,678 Ceased US7341748B2 (en) | 2004-04-28 | 2005-04-27 | Crude extracts from Andrographis paniculata |
US12/717,260 Active USRE42718E1 (en) | 2004-04-28 | 2010-03-04 | Crude extracts from andrographis paniculata |
Country Status (14)
Country | Link |
---|---|
US (3) | US7341748B2 (en) |
EP (1) | EP1747008B1 (en) |
JP (1) | JP5221128B2 (en) |
KR (3) | KR101536892B1 (en) |
AU (1) | AU2005237550B2 (en) |
CA (1) | CA2564637C (en) |
DK (1) | DK1747008T3 (en) |
ES (1) | ES2534594T3 (en) |
HU (1) | HUE025117T2 (en) |
PL (1) | PL1747008T3 (en) |
PT (1) | PT1747008E (en) |
RU (1) | RU2383353C2 (en) |
TW (1) | TWI373340B (en) |
WO (1) | WO2005104722A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090117210A1 (en) * | 2007-11-02 | 2009-05-07 | Hutchison Medipharma Enterprises Limited | Andrographis paniculata extract |
US20110142944A1 (en) * | 2006-02-28 | 2011-06-16 | Hutchison Medipharma Enterprises Limited, Offshore Group Chambers | Andrographis extract formulations |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200536526A (en) * | 2004-03-11 | 2005-11-16 | Hutchison Medipharma Entpr Ltd | Andrographolide and analogues as inhibitors of TNF-alpha and IL-1 β expression |
ES2534594T3 (en) | 2004-04-28 | 2015-04-24 | Nutrition Science Partners Limited | Raw extracts of Andrographis paniculata |
JP2007176934A (en) * | 2005-11-30 | 2007-07-12 | Kose Corp | Platelet-activating factor acetylhydrolase function regulator |
EP1882473A1 (en) * | 2006-07-28 | 2008-01-30 | Indena S.P.A. | Use of anthocyanosides to prepare formulations for the treatment of mucositis induced by antitumoral drugs |
WO2010110748A1 (en) * | 2009-03-24 | 2010-09-30 | National University Of Singapore | Use of andrographolide compounds for treating inflammation and airway disorders |
MD480Z (en) * | 2011-07-07 | 2012-09-30 | Elvira Andon | Method for treating acute ulcerative nonspecific colitis |
CN102702147B (en) * | 2012-06-18 | 2016-06-08 | 辽宁利锋科技开发有限公司 | The application of andrographolide analog and treatment thereof |
CN103145661B (en) * | 2013-03-25 | 2014-06-18 | 成都天台山制药有限公司 | New crystal form of andrographolide |
CN103145660B (en) * | 2013-03-25 | 2014-09-17 | 成都天台山制药有限公司 | Andrographolide and preparation method thereof |
CN103223028A (en) * | 2013-03-27 | 2013-07-31 | 张宗升 | Extract product of traditional Chinese medicine |
CN103766901A (en) * | 2014-01-08 | 2014-05-07 | 浙江大学 | Application of andrographolide C to preparation of weight-losing food or medicine |
JP6386761B2 (en) * | 2014-03-19 | 2018-09-05 | 花王株式会社 | Involucrin expression inhibitor |
MY176459A (en) | 2016-05-23 | 2020-08-10 | Univ Putra Malaysia | Extract of andrographis paniculata for cognitive enhancement |
WO2018081959A1 (en) | 2016-11-02 | 2018-05-11 | Nutrition Science Partners Limited | Extracts of andrographis paniculata, methods for preparation and use thereof |
CN107349253A (en) * | 2017-06-23 | 2017-11-17 | 苏州凌科特新材料有限公司 | Non-stimulated Medical antiseptic solution and preparation method thereof |
WO2022058422A1 (en) * | 2020-09-17 | 2022-03-24 | Dsm Ip Assets B.V. | Use of andrographis paniculata extract to protect against air pollution related diseases |
Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1042077A (en) | 1989-07-29 | 1990-05-16 | 郭如明 | Alkali-water process for creat |
JP2000034233A (en) | 1998-07-15 | 2000-02-02 | Sumitomo Forestry Co Ltd | Inhibitor of production of nitric oxide |
JP2001058969A (en) | 1999-08-20 | 2001-03-06 | Nettairin Saisei Gijutsu Kenkyu Kumiai | Nitrogen monoxide production inhibitor |
US6358526B1 (en) | 2000-08-16 | 2002-03-19 | Rexall Sundown | Method of making tablets and tablet compositions produced therefrom |
US20020068098A1 (en) | 2000-08-01 | 2002-06-06 | Ashni Naturaceuticals, Inc. | Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2 |
US20030059471A1 (en) | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
US20030091517A1 (en) | 2001-11-09 | 2003-05-15 | Mahidol University | Andrographis paniculata gel as an adjunct in the treatment of periodontitis |
US20030101076A1 (en) | 2001-10-02 | 2003-05-29 | Zaleski John R. | System for supporting clinical decision making through the modeling of acquired patient medical information |
US20030104076A1 (en) | 2001-11-07 | 2003-06-05 | Wilhelm Berkulin | Process for preparing dry extracts |
JP2004075638A (en) | 2002-08-21 | 2004-03-11 | Okinawa Pref Gov | Functional material having action to suppress increase of blood sugar level and suppress increase of blood pressure |
US20040053858A1 (en) | 2000-07-28 | 2004-03-18 | Berg Kurt Frimann | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
CN1488376A (en) | 2003-05-09 | 2004-04-14 | 江西诚志信丰药业有限责任公司 | Medicinal cap sule for treating enteric disease and nusosinusitis and preparing method thereof |
US20040151792A1 (en) | 2001-06-20 | 2004-08-05 | Tripp Matthew L. | Compositions that treat or inhibit pathological conditions associated with inflammatory response |
CN1626076A (en) | 2003-12-11 | 2005-06-15 | 天津天士力制药股份有限公司 | Andrographolide drop pills and preparation method |
CN1628764A (en) | 2004-08-19 | 2005-06-22 | 贵阳云岩西创药物科技开发有限公司 | Creat formulation and its preparation process |
KR20050067951A (en) | 2003-12-29 | 2005-07-05 | 주식회사 엘지생활건강 | Andrographolide or andrographis paniculata extract containing composition having anti-itching effect |
WO2005087223A1 (en) | 2004-03-11 | 2005-09-22 | Hutchison Medipharma Ltd. | ANDROGRAPHOLIDE AND ANALOGUES AS INHIBITORS OF TNFα AND IL-1βEXPRESSION |
WO2005104722A2 (en) | 2004-04-28 | 2005-11-10 | Hutchison Medipharma Enterprises Limited | Crude extracts from andrographis paniculata |
US20070202164A1 (en) | 2006-02-28 | 2007-08-30 | Hutchison Medipharma Enterprises Limited | Andrographis Extract Formulations |
US20070218114A1 (en) | 2004-06-12 | 2007-09-20 | Passionfor Life Healthcare Limited | Soluble Strip for Oral or Topical Administration |
WO2009059158A1 (en) | 2007-11-02 | 2009-05-07 | Hutchison Medipharma Enterprises Limited | Andrographis paniculata extract |
-
2005
- 2005-04-26 ES ES05742174.5T patent/ES2534594T3/en active Active
- 2005-04-26 DK DK05742174T patent/DK1747008T3/en active
- 2005-04-26 KR KR1020157010077A patent/KR101536892B1/en active IP Right Grant
- 2005-04-26 HU HUE05742174A patent/HUE025117T2/en unknown
- 2005-04-26 PL PL05742174T patent/PL1747008T3/en unknown
- 2005-04-26 KR KR1020067025043A patent/KR101534844B1/en active IP Right Grant
- 2005-04-26 EP EP05742174.5A patent/EP1747008B1/en active Active
- 2005-04-26 JP JP2007510891A patent/JP5221128B2/en not_active Expired - Fee Related
- 2005-04-26 KR KR1020137001151A patent/KR101531116B1/en active IP Right Grant
- 2005-04-26 WO PCT/US2005/014288 patent/WO2005104722A2/en active Application Filing
- 2005-04-26 CA CA2564637A patent/CA2564637C/en active Active
- 2005-04-26 AU AU2005237550A patent/AU2005237550B2/en not_active Ceased
- 2005-04-26 PT PT05742174T patent/PT1747008E/en unknown
- 2005-04-26 RU RU2006141834/14A patent/RU2383353C2/en active
- 2005-04-27 US US11/116,678 patent/US7341748B2/en not_active Ceased
- 2005-04-27 TW TW094113415A patent/TWI373340B/en active
-
2010
- 2010-03-04 US US12/717,260 patent/USRE42718E1/en active Active
-
2011
- 2011-07-22 US US13/189,444 patent/USRE43423E1/en active Active
Patent Citations (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1042077A (en) | 1989-07-29 | 1990-05-16 | 郭如明 | Alkali-water process for creat |
US20030059471A1 (en) | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
JP2000034233A (en) | 1998-07-15 | 2000-02-02 | Sumitomo Forestry Co Ltd | Inhibitor of production of nitric oxide |
JP2001058969A (en) | 1999-08-20 | 2001-03-06 | Nettairin Saisei Gijutsu Kenkyu Kumiai | Nitrogen monoxide production inhibitor |
US20040053858A1 (en) | 2000-07-28 | 2004-03-18 | Berg Kurt Frimann | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
US20020068098A1 (en) | 2000-08-01 | 2002-06-06 | Ashni Naturaceuticals, Inc. | Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2 |
US6358526B1 (en) | 2000-08-16 | 2002-03-19 | Rexall Sundown | Method of making tablets and tablet compositions produced therefrom |
US20040151792A1 (en) | 2001-06-20 | 2004-08-05 | Tripp Matthew L. | Compositions that treat or inhibit pathological conditions associated with inflammatory response |
US20030101076A1 (en) | 2001-10-02 | 2003-05-29 | Zaleski John R. | System for supporting clinical decision making through the modeling of acquired patient medical information |
US20030104076A1 (en) | 2001-11-07 | 2003-06-05 | Wilhelm Berkulin | Process for preparing dry extracts |
US20030091517A1 (en) | 2001-11-09 | 2003-05-15 | Mahidol University | Andrographis paniculata gel as an adjunct in the treatment of periodontitis |
JP2004075638A (en) | 2002-08-21 | 2004-03-11 | Okinawa Pref Gov | Functional material having action to suppress increase of blood sugar level and suppress increase of blood pressure |
CN1488376A (en) | 2003-05-09 | 2004-04-14 | 江西诚志信丰药业有限责任公司 | Medicinal cap sule for treating enteric disease and nusosinusitis and preparing method thereof |
CN1626076A (en) | 2003-12-11 | 2005-06-15 | 天津天士力制药股份有限公司 | Andrographolide drop pills and preparation method |
KR20050067951A (en) | 2003-12-29 | 2005-07-05 | 주식회사 엘지생활건강 | Andrographolide or andrographis paniculata extract containing composition having anti-itching effect |
WO2005087223A1 (en) | 2004-03-11 | 2005-09-22 | Hutchison Medipharma Ltd. | ANDROGRAPHOLIDE AND ANALOGUES AS INHIBITORS OF TNFα AND IL-1βEXPRESSION |
US20050215628A1 (en) | 2004-03-11 | 2005-09-29 | Hutchison Medipharma Ltd. | Andrographolide and analogues as inhibitors of TNFalpha and IL-1beta expression |
US7625945B2 (en) | 2004-03-11 | 2009-12-01 | Hutchison MediPharma Enterprises Ltd. | Andrographolide and analogues as inhibitors of TNFα and IL-1β expression |
WO2005104722A2 (en) | 2004-04-28 | 2005-11-10 | Hutchison Medipharma Enterprises Limited | Crude extracts from andrographis paniculata |
US20060246156A1 (en) | 2004-04-28 | 2006-11-02 | Hutchinson Medipharma Enterprises Limited | Crude extracts from andrographis paniculata |
US7341748B2 (en) | 2004-04-28 | 2008-03-11 | Hutchison Medipharma Enterprises Limited | Crude extracts from Andrographis paniculata |
US20070218114A1 (en) | 2004-06-12 | 2007-09-20 | Passionfor Life Healthcare Limited | Soluble Strip for Oral or Topical Administration |
CN1628764A (en) | 2004-08-19 | 2005-06-22 | 贵阳云岩西创药物科技开发有限公司 | Creat formulation and its preparation process |
WO2007098686A1 (en) | 2006-02-28 | 2007-09-07 | Hutchison Medipharma Enterprises Limited | Andrographis extract formulations |
US20070202164A1 (en) | 2006-02-28 | 2007-08-30 | Hutchison Medipharma Enterprises Limited | Andrographis Extract Formulations |
WO2009059158A1 (en) | 2007-11-02 | 2009-05-07 | Hutchison Medipharma Enterprises Limited | Andrographis paniculata extract |
US20090117209A1 (en) | 2007-11-02 | 2009-05-07 | Hutchison Medipharma Enterprises Limited | Andrographis paniculata extract |
US20090117210A1 (en) | 2007-11-02 | 2009-05-07 | Hutchison Medipharma Enterprises Limited | Andrographis paniculata extract |
Non-Patent Citations (173)
Title |
---|
Achike et al., "Nitric Oxide, Human Diseases and the Herbal Products that Effect the Nitric Oxide Signalling Pathway," Clinical & Experimental Pharmacology & Physiology, 30: 605-615 (2003). |
Advisory Action mailed Mar. 25, 2011, in Reissue U.S. Application No. 12/717,260. |
Akbarsha et al., "Antifertility effect of Andrographis paniculata (nees) in male albino rat," Indian Journal of Experimental Biology, 28:421-426 (1990). |
Akbarsha et al., Antifertility effect of Andrographis paniculata (nees) in male albino rat, Indian Journal of Experimental Biology, 28:421-426, 1990. |
Amendment and Reply Under 37 C.F.R. § 1.114 filed Sep. 18, 2009, in U.S. Appl. No. 11/934,143. |
Amendment and Reply under 37 U.S.C. § 1.114, filed Dec. 15, 2010, in U.S. Appl. No. 11/934,143. |
Amendment and Response to Election Requirement filed Apr. 13, 2011, in U.S. Appl. No. 12/264,646. |
Amendment in Reply to Action of Aug. 1, 2006 filed Dec. 1, 2006, in U.S. Appl. No. 11/116,678. |
Amendment in reply to Communication pursuant to Article 94(3) EPC of Dec. 3, 2009 filed Jun. 3, 2010, in EP 1747008. |
Amendment in Reply to Non-Final Office Action of Jul. 7, 2008 with Exhibits A & B, filed Nov. 7, 2008, in U.S. Appl. No. 11/934,143. |
Andrographis Paniculata Tablets, The Pharmacopoeia of People's Republic of China (2000 ed.), vol. I, p. 541 (2000). |
Andrographis Paniculata Tablets, The Pharmacopoeia of People's Republic of China (2005 ed.), vol. I, pp. 549-550 (2005). |
Assche et al., "Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial," Gut 55;1568-1574 (2006). |
Balmain et al., "Minor Diterpenoid Constituents of Andrographis paniculata Nees," J. Chem. Soc. Perkin. Trans. I (1973): 1247-1251. |
Bao W., "Determination of Dehydroandrographolide in Andrographis paniculata Tablets by FIA," Chinese Traditional Patent Medicine, 25(12):976-978 (2003). |
Basak et al., "Implication of the protein convertases furin, PC5 and PC7 in the cleavage of surface glycoproteins of Hong Kong, Ebola and respiratory syncytial viruses: a comparative analysis with fluorogenic peptides," Biochem J., 353:537-545 (2001). |
Basak et al., "Implication of the protein convertases furin, PC5 and PC7 in the cleavage of surface glycoproteins of Hong Kong, Ebola and respiratory syncytial viruses: a comparative analysis with fluorogenic peptides", Biochem J., 353:537-45, 200, abstract. |
Bhan et al., "Screening and optimization of Andrographis paniculata (Burm.f.) Nees for total andrographolide content, yield and its components," Scientia Horticulturae, 107: 386-391 (2006). |
Burgos et al., "Testicular toxicity assessment of Andrographis paniculata dried extract in rats," J. Ethnopharmacol., 58(3): 219-224 (1997). |
Cai S., et al., "Factors impacting the determination of andrographolide and dehydroandrographolide content in Andrographis paniculata tablets," Chinese Traditional Patent Medicine, 27(3):361-362 (2005). |
Calabrese et al., "A Phase I Trial of Andrographolide in HIV Positive Patients and Normal Volunteers," Phytother Res., 14:333-338 (2000). |
Calabrese et al., A Phase I Trial of Andrographolide in HIV Positive Patients and Normal Volunteers, Phytother. Res. 14:333-338, 2000. |
Chang et al., "Dehydroandrographolide succinic acid monoester as an inhibitor against the human immunodeficiency virus," Proc. Soc. Exp. Biol. Med., 197(1): 59-66 (1991). |
Chen et al. , "Studies on flavonoids of Andrographis paniculata, " China J. Chinese Materia Medica., 31(5):391-395 (2006), Abstract only. |
Chen et al., "Nine new ent-labdane diterpenoids from the aerial parts of Andrographis paniculata," Helvetica Chimica Acta, 89:2654-2664 (2006). |
Chen et al., "Studies on diterpenoids from Andrographis paniculata," China J. Chinese Materia Medica., 31(19):1594-1597 (2006), Abstract only. |
Communication pursuant to Article 94(3) EPC in EP 1747008, dated Dec. 3, 2009. |
Communication pursuant to Article 94(3) EPC in EP 1747008, dated Feb. 24, 2011. |
Communication pursuant to Article 94(3) EPC in EP 1747008, dated Jul. 5, 2010. |
Communication pursuant to Article 94(3) EPC in European Patent Application No. 05742174.5, dated Sep. 27, 2011. |
Communication pursuant to Rule 114(2) EPC in EP1996165, dated Apr. 29, 2010, enclosing Third Party Observations. |
Coon et al., "Andrographis paniculata in the Treatment of Upper Respiratory Tract Infections: A Systematic Review of Safety and Efficacy," Planta Med., 70(4): 293-298 (2004). |
Deng et al., Chinese Pharm. Bull., 17:195-198 (1982), Abstract only. |
English translation of JP 2000034233 A-2000. * |
Ex parte Subramanyam (BPAI, Mar. 29, 2010). |
Feagan et al., "Omega-3 Free Fatty Acids for theMaintenance of Remission in Crohn Disease," JAMA, 299(14):1690-1697 (2008). |
Feng Y., et al., "Determination of deoxyandrographolide content in Andrographis paniculata tablets by TLC scanning," Chinese Traditional Patent Medicine, 14(5):17-18 (1992). |
Final Office Action mailed Feb. 21, 2007, in U.S. Appl. No. 11/116,678. |
Final Office Action mailed Feb. 9, 2011, in Reissue U.S. Appl. No. 12/717,260. |
Final Office Action mailed Jan. 4, 2010, in U.S. Appl. No. 11/674,557. |
Final Office Action mailed Jun. 16, 2010, in U.S. Appl. No. 11/934,143. |
Final Office Action mailed Mar. 20, 2009, in U.S. Appl. No. 11/934,143. |
Final Office Action mailed Oct. 18, 2011, in U.S. Appl. No. 11/934,143. |
Fujita et al., "On the diterpenoids of Andrographis paniculata: x-ray Crystallographic analysis of andrographolide and structure determination of new minor diterpenoids," Chem. Pharm. Bull., 32(6):2117-2125 (1984). |
George et al., "Investigations on plant antibiotics. Part IV. Further search for antibiotic substances in Indian medicinal plants," Indian Journal of Medical Research, (37): 169-181 (2004). |
Ghosh et al., "Isolation of Andrographis paniculata leaf protein with antifungal property," Acto. Phytopathologica et Entomologica Hungarica, 39(4):377-381 (2004). |
Guidance for Industry Botanical Drug Products, U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Jun. 2004. |
Gupta et al., "Antidiarrheal activity of diterpenes of Andrographis paniculata (kalmegh) against Escherichia coli enterotoxin in in vivo models," International Journal of Crude Drug Research, (28): 273-283 (1990). |
Gupta et al., "Antisecretory (antidiarrhoeal) activity of Indian medicinal plants against Escherichia coli enterotoxin-induced secretion in rabbit and guinea pig ileal loop models," lnl. J, Pharmacog., 31(3):198-204 (1993). |
Gupta et al., "Flavonoid glycoside of Andrographis paniculata," Indian J. Chem., 35 B:512-513 (1996). |
Gupta et al., "Flavonoids of Andrographis paniculata," Phytochemistry, 22(1):314-315 (1983). |
Habtemariam, "Andrographolide inhibits the tumour necrosis Factor-alpha-induced upregulation of ICAM-1 expression and endothelial-monocyte adhesion," Phytotherapy Research, 12:37-40 (1998). |
Habtemariam, "Natural Inhibitors of Tumor Necrosis Factor-alpha Production, Secretion and Function," Planta Medica, 66:303-313 (2000). |
Habtemariam, "Andrographolide Inhibits the Tumor Necrosis Factor-Alpha-Induced Upregulation of ICAM-1 Expression and Endothelial-Monocyte Adhesion" Phytotherapy Research (1998) vol. 12, No. 1, pp. 37-40, abstract. |
Habtemariam, "Andrographolide inhibits the tumour necrosis Factor-α-induced upregulation of ICAM-1 expression and endothelial-monocyte adhesion," Phytotherapy Research, 12:37-40 (1998). |
Habtemariam, "Natural Inhibitors of Tumor Necrosis Factor-α Production, Secretion and Function," Planta Medica, 66:303-313 (2000). |
Habtemariam, S., "Andrographolide inhibits the tumor necrosis factor-.alpha .-induced upregulation of ICAM-1 expression and endothelial-monocyte adhesion", Phytotherapy Research, 12(1):37-40, 1998, abstract. |
Hancke et al., "A double-blind study with a new monodrug: decrease of symptoms and improvement of recovery from common colds," Phytotherapy Research, (9): 559-562 (1995). |
Hasko, Immunology, 103L 473-478 (2001). |
Herba Andrographis, World Health Organization (WHO) monographs on selected medicinal plants, vol. 2. pp. 12-24 (2002). |
Herbs, Andrographis paniculata's wide range of medicinal Powers, (2002). |
Huang P. et al., "Determination of dehydroandrographolide content in Andrographis paniculata tablets by HPLC," Journal of Guangxi Traditional Chinese Medical University, 7(3):70-71 (2004). |
Jalal et al., "Formation of three new Flavones by differentiating callus cultures of Andrographis paniculata," Phytochemistry, 18:149-151 (1979). |
Jantan et al., "Ent-14beta-Hydroxy-8(17),12-Labdadien-16,15-Olide-3beta,19 Oxdide: a Diterpene from the aerial parts of Andrographis paniculata," Phytochemistry, 37(5):1477-1479 (1994). |
Jantan et al., "Ent-14β-Hydroxy-8(17),12-Labdadien-16,15-Olide-3β,19 Oxdide: a Diterpene from the aerial parts of Andrographis paniculata," Phytochemistry, 37(5):1477-1479 (1994). |
Jiang Zemin, President of the People's Republic of China, Pharmaceutical Administration Law of the People's Republic of China (2001). |
Jianguo Ji, "Declaration under 37 C.F.R. § 1.132" with Exhibits 1, dated Dec. 20, 2010. |
Jianguo Ji, "Declaration under 37 C.F.R. § 1.132" with Exhibits 1-4, filed on Dec. 15, 2010, in U.S. Appl. No. 11/934,143. |
Jifeng Duan, "Declaration under 37 C.F.R. § 1.132," filed on Dec. 15, 2010, in U.S. Appl. No. 11/934,143. |
Kakrani et al., "Traditional treatment of gastro-intestinal tract disorders in Kutch district, Gujarat state, India," Journal of Natural Remedies, 2/1: 71-75 (2002). |
Kleipool, "Constituents of Andrographis paniculata nees," Nature, 169(4288):33-34 (1952). |
Kumar et al., "Anticancer and immunomodulatory potential of DRF-3188, an analogue of andrographolide," Novel Compounds from Natural Products in the New Millenium, 205-216, (2004). (Abstract). |
Kumar, et al., "Anticancer and immunomodulatory potential of DRF-3188, an analogue of andrographolide", Novel Compounds from Natural Products in the New Millenium, 205-216, 2004, abstract. |
Li Wang, "Declaration under 37 C.F.R. § 1.132," filed on Dec. 15, 2010, in U.S. Appl. No. 11/934,143. |
Madav et al., "Analgesic, antipyretic and antiulcerogenic effects of andrographolide," Indian J. Pharm. Sci., 57(3):121-125 (1995). |
Madav et al., "Anti-inflammatory activity of andrographolide," Fitoterapia, 67:452-458, (1996). |
Mahadevan et al., "Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease," Am. J. Gastroenterology, 97(4): 910-4 (2002) (Abstract). |
Matsuda et al., "Cell differentiation-inducing diterpenes from Andrographis paniculata Nees," Chem. Pharm. Bull., 42(6):1216-1225 (1994). |
Matsuda et al., "Studies on the cell differentiation induces of Andrographis paniculata," Tennen Yuki Kagobutsu Toronkai Koen Yoshishu, 33:433-440 (1991) (Abstract). |
Melchior et al., "Double-blind, placebo-controlled pilot and phase III study of activity of standardized Andrographis paniculata Herba Nees extract fixed combination (Kan jang) in the treatment of uncomplicated upper-respiratory tract infection," Phytomedicine, 7(5): 341-350 (2000). |
Mishra et al., "Andrographis paniculata (Kalmegh): A Review," Pharmacognosy Reviews, 1(2):283-298 (2007). |
Misra et al., "Antimalarial activity of traditional plants against erythrocytic stages of Plasmodium berghei," International Journal of Pharmacognosy, (29): 19-23 (1991). |
Nazimudeen et al., "Effect of Andrographis paniculata on snake venom-induced death and its mechanism," Indian Journal of Pharmaceutical Sciences, (40):132-133 (1978). |
Notice of Allowance and Fee(s) Due mailed Jul. 1, 2011, in Reissue U.S. Appl. No. 12/717,260. |
Notice of Appeal under 37 C.F.R. § 41.31 and Appeal Brief Under Board Rule § 41.37, both filed Jan. 18, 2012, in U.S. Appl. No. 11/934,143. |
Office Action mailed Aug. 1, 2006, in U.S. Appl. No. 11/116,678. |
Office Action mailed Dec. 15, 2009, in U.S. Appl. No. 11/934,143. |
Office Action mailed Jul. 7, 2008, in U.S. Appl. No. 11/934,143. |
Office Action mailed Jun. 16, 2010, in U.S. Appl. No. 11/674,557. |
Office Action mailed Jun. 2, 2009, in U.S. Appl. No. 11/674,557. |
Office Action mailed Jun. 23, 2010, in Reissue U.S. Appl. No. 12/717,260. |
Office Action mailed May 12, 2011, in U.S. Appl. No. 11/934,143. |
Office Action mailed May 13, 2011, in U.S. Appl. No. 12/264,646. |
Otake et al., "Screening of Indonesian plant extracts for anti-human immunodeficiency virus type 1 (HIV-1) activity," Phytotherapy Research, (9): 6-10 (1995). |
Panossian et al., "Effect of Andrographis paniculata extract on progesterone in blood plasma of pregnant rats," Phytomedicine, 6(3): 157-161 (1999). |
Panossian et al., "Effect of Andrographis paniculata extract on progesterone in blood plasma of pregnant rats," Phytomedicine, 6(3):157-161 (1999). (Abstract). |
Panossian et al., "Effect of andrographolide and Kan Jang-fixed combination of extract SHA-10 and extract SHE-3-on proliferation of human lymphocytes, production of cytokines and immune activation markers in the whole blood cells culture," Phytomedicine, 9(7):598-605 (2002). (Abstract). |
Panossian, et al., "Effect of andrographolide and Kan Jang—fixed combination of extract SHA-10 and extract SHE-3—on proliferation of human lymphocytes, production of cytokines and immune activation markers in the whole blood cells culture", Phytomedicine, 9(7):598-605, 2002, abstract. |
PCT International Preliminary Report on Patentability issued Sep. 2, 2008, in International Application No. PCT/CN2007/000616. |
PCT International Preliminary Report on Patentability mailed Nov. 9, 2006, in International Appication No. PCT/US2005/14288. |
PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, mailed Sep. 13, 2006, in International Application No. PCT/US2005/008317. |
PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, mailed Dec. 9, 2005, in International Application No. PCT/US05/14288. |
PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, mailed Jan. 26, 2009, in International Application No. PCT/US2008/082022. |
PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, mailed Jun. 7, 2007, in International Application No. PCT/CN2007/000616. |
Peng et al., "Modulation of Lianbizi injection (andrographolide) on some immune functions," Zhongguo Zhongyao Zazhi, 27(2):147-150 (2002) (Abstract). |
Poolsup et al., "Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials," J. Clin. Pharm. Ther, 29(1): 37-45 (2004). |
Practical Techniques for National Qualification Examination of Professional Skills in Chinese medication, Professional Skills, Shanghai Science and Technology Press, China, p. 164 (2003). |
Pramanick et al., "Andropanolide and isoandrographolide, minor diterpenoids from Andrographis paniculata: structure and X-ray crystallographic analysis," J. Nat. Prod., 69: 403-405 (2006). |
Pre-IND Submission Meeting Briefing Document (Redacted) (2005). |
Puri et al., "Immunostimulant agents from Andrographis Paniculata," Journal of National Products, 56(7):995-999 (1993). |
Puri et al., "Immunostimulant Agents from Andrographis Paniculata," Journal of National Products, vol. 56, No. 7, pp. 995-999 (1993). |
Qian et al., "A comparison of pharmacological effects between CXL extract and CXL compound prescription," Journal of Luzhou Medical School, 11(3): 189-191 (1988), Abstract only. |
Rajagopal et al., "Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata," Journal of Experimental Therapeutics and Oncology, 3(3):147-158 (2003). (Abstract). |
Rajagopal, et al., "Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata" , Journal of Experimental Therapeutics and Oncology, 3(3):147-158, 2003, abstract. |
Rao et al., "Flavonoids and andrographolides from Andrographis paniculata," Phytochemistry, 65(16):2317-2321 (2004). (Abstract). |
Reddy et al., "A flavone and an unusual 23-carbon terpenoid from Andrographis paniculata," Phytochemistry, 62:1271-1275 (2003). |
Reddy et al., "A new BIS-Andrographolide ether from Andrographis paniculata Nees and evaluation of anti-HIV activity," Natural Product Research, 19(3):223-230 (2005). |
Reply to Action of Feb. 21, 2007 with Exhibit A, filed May 21, 2007, in U.S. Appl. No. 11/116,678. |
Reply to Communication pursuant to Article 94(3) EPC of Jul. 5, 2010 filed Jan. 14, 2011, in EP 1747008. |
Reply to Final Office Action; filed Mar. 10, 2011, in Reissue U.S. Appl. No. 12/717,260. |
Reply to Office Action filed Aug. 15, 2011, in U.S. Appl. No. 12/264,646. |
Reply to Office Action filed Mar. 15, 2010, in U.S. Appl. No. 11/934,143. |
Reply to Office Action filed Oct. 1, 2009, in U.S. Appl. No. 11/674,557. |
Reply to Office Action; filed Dec. 21, 2010, in Reissue U.S. Appl. No. 12/717,260. |
Reply to Office filed Jul. 21, 2011, in U.S. Appl. No. 11/934,143. |
Restriction Requirement mailed Mar. 21, 2011, in U.S. Appl. No. 12/264,646. |
Rutgeerts et al., "Onercept for Moderate-to-Severe Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial," Clinical Gastroenterology and Hepatology, 4:888-893 (2006). |
Sandborn et al., "Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis," Gut, 59: 1485-1492 (2010). |
Saxena et al., "Phytochemicals from Andrographis paniculata," Indian J. Chem., 42B:3159-3163 (2003). |
Saxena et al., "High-performance thin-layer chromatographic analysis of heptoprotective diterpenoids from Andrographis paniculata," Phytochem Anal, 11:34-36 (2000). |
See et al., "Increased tumor necrosis factor alpha (TNF-. alpha.) and natural killer cell (NK) function using an integrative approach in late stage cancers," Immunological Investigations, 31(2):137-153 (2002). (Abstract). |
See, et al., "Increased tumor necrosis factor alpha (TNF-. alpha.) and natural killer cell (NK) function using an integrative approach in late stage cancers", Immunological Investigations, 31(2):137-153, 2002, abstract. |
Shen et al., "Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism(s) involve in its anti-inflammatory effect," British Journal of Pharmacology, 135:399-406 (2002). |
Shen et al., "ent-Labdane diterpenoids from Andrographis paniculata," J. Nat. Prod., 69:319-322 (2006). |
Shen et al., "Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism(s) involve in its anti-inflammatory effect", British Journal of Pharmacology 135:349-405, 2002. |
Singha et al., "Antimicrobial activity of Andrographis paniculata," Fitoterapia, 74:692-694 (2003). |
Singha et al., "Antimicrobial activity of Andrographis paniculata," Fitoterapia, 74:692-694, 2003. |
Slide presented to FDA in Jul. 2010. |
Supplementary Reply Under 37 C.F.R. § 1.116, Terminal Disclaimer, and Supplemental Reissue Declaration under 37 C.F.R. § 1.175, filed Apr. 6, 2011, in Reissue U.S. Appl. No. 12/717,260. |
Tang et al., "Herbal extract HMPL-004 in Active Ulcerative Colitis: A Randomized Comparison with Sustained Release Mesalamine," American Journal of Gastroenterology (2010). |
Tao Wang, "Declaration under 37 C.F.R. § 1.132," filed on Dec. 15, 2010, in U.S. Appl. No. 11/934,143. |
Thamaree et al., "The effect of andrographolide on the production of proinflammatory cytokines by in vitro stimulated human blood cells," Inflammation Res., 46, Suppl. 3, S224, (1997). (Abstract). |
Tharmaree, et al., "The effect of andrographolide on the production of proinflammatory cytokines by in vitro stimulated human blood cells", Inflammation Res., 46, Suppl. 3, S224, 1997, abstract. |
Townsend et al., "Extracts of Chinese Herbs Inhibit IL-Ibeta- and UV-induced MMP Expression in Cultured Human Keratinocytes," FASEB Journal, 15(4): A184 (2001). |
Townsend et al., "Extracts of Chinese Herbs Inhibit IL-Ibeta- and UV-induced MMP Expression in Cultured Human Keratinocytes," FASEB Journel, Mar. 2001, vol. 15, No. 4, p. A184. |
Trivedi et al., "Hepatoprotective and antioxidant property of Andrographis paniculata (Nees) in BHC induced liver damage in mice," Indian J. Exp. Biol., 39(1):41-6 (2001). (Abstract). |
Trivedi et al., "Hepatoprotective and antioxidant property of Andrographis paniculata (Nees) in BHC induced liver damage in mice" Indian J. Exp. Biol. 39(1):41-6, 2001, abstract. |
Vedavathy et al., "Antipyretic activity of six indigenous medicinal plants of Tirumala Hills, Andhra Pradesh, India," Journal of Ethnopharmacology, 33(1-2): 193-196 (1991). |
Wang et al., "A Discussion on the effect of the extraction process of Chinese traditional medicine on the quality of the resulting drug," Heilongjiang Chinese Medicine, No. 2: 45-46 (1992). |
Wang et al., "Andrographolide reduces inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuron-glia cultures by inhibiting microglial activation," Journal of Pharmacology and Experimental Therapeutics, 308(3):915-983 (2004) (Abstract). |
Wang et al., "Chemical constituents from leaves of Andrographis paniculata," J. China Pharma. Univ., 36(5):405-407 (2005), Abstract only. |
Weihan Zhang, "Declaration under 37 C.F.R. § 1.132," filed on Dec. 15, 2010, in U.S. Appl. No. 11/934,143. |
Weihan Zhang, "First Declaration under 37 C.F.R. § 1.132," dated Dec. 21, 2010. |
Weihan Zhang, "First Declaration under 37 C.F.R. § 1.132," filed on Dec. 15, 2010, in U.S. Appl. No. 11/934,143. |
Weihan Zhang, "Second Declaration under 37 C.F.R. § 1.132," dated Dec. 21, 2010. |
Weihan Zhang, "Second Declaration under 37 C.F.R. § 1.132," filed on Dec. 15, 2010, in U.S. Appl. No. 11/934,143. |
Weihan Zhang, Third Declaration Under 37 C.F.R § 1.132, dated Mar. 10, 2011. |
William J. Sandborn, "Declaration of William J. Sandborn, M.D., under 37 C.F.R. § 1.132" with Exhibit 1, filed on Dec. 15, 2010, in U.S. Appl. No. 11/934,143. |
Xia, "Andrographolide Attenuates Inflammation by Inhibition of NF-kB Activation Through Covalent Modification of Reduced Cysteine 62 of p501," The Journal of Immunology, 4207-4217 (2004). |
Xiaoqiang Yan, "Declaration under 37 C.F.R. § 1.132," filed on Dec. 15, 2010, in U.S. Appl. No. 11/934,143. |
Xun Zhang, "Declaration under 37 C.F.R. § 1.132," filed on Dec. 15, 2010, in U.S. Appl. No. 11/934,143. |
Yao et al, "Mechanism of inhibition of HIV-1 infection in vitro by a purified extract of Prunella vulgaris," Virology, 187(1): 56-62 (1992). |
Yu Cai, "Declaration under 37 C.F.R. § 1.132," filed on Dec. 15, 2010, in U.S. Appl. No. 11/934,143. |
Yuqing Wang, "Declaration under 37 C.F.R. § 1.132," filed on Dec. 15, 2010, in U.S. Appl. No. 11/934,143. |
Zhang et al., "Antihyperglycaemic and anti-oxidant properties of andrographis paniculata in normal and diabetic rats," Clinical and Experimental Pharmacology and Physiology, 27:358-363 (2000). |
Zhang et al., "Effects of 14-Deoxyandrographolide and 14-Deoxy-11, 12-Didehydroandrographolide on Nitric Oxide Production in Cultured Human Endothelial Cells," Phytotherapy Research, 13:157-159 (1999). |
Zhang et al., "Experimental Studies of the destructive actions of Andrographis paniculata nees on endotoxin in vitro," Chinese J. of Integrated Traditional and Western Medicine in Intensive and Critical Care, 7(4):212-214 (2000), Abstract only. |
Zhang et al., "New Diterpenoids from Andrographis paniculata (Burm. f.) nees," J. of Integrative Plant Biology, 48(9): 1122-1125 (2006). |
Zhang et al., "Antihyperglycaemic and anti-oxidant properties of Andrographis paniculata in normal and diabetic rats," Clinical and Experimental Pharmacology and Physiology, 27:358-363, (2000). |
Zhao et al., "Determination of andrographolide, deoxyandrographolide and neoandrographolide in the Chinese herb Andrographis paniculata by micellar electrokinetic capillary chromatography," Phytochem Anal, 13: 222-227 (2002). |
Zhiming Ma, "Declaration under 37 C.F.R. § 1.132," filed on Dec. 15, 2010, in U.S. Appl. No. 11/934,143. |
Zhong et al., "Three salts of labdanic acids from Andrographis paniculata (Acanthaceae)," Acta Botanica Sinica, 43:1077-1080 (2001). |
Zhou et al., "Two new ent-labdane diterpenoid glycosides from the aerial parts of Andrographis paniculata," Journal of Asian Natural Products Research, 10(10):939-943 (2008). |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110142944A1 (en) * | 2006-02-28 | 2011-06-16 | Hutchison Medipharma Enterprises Limited, Offshore Group Chambers | Andrographis extract formulations |
US20090117210A1 (en) * | 2007-11-02 | 2009-05-07 | Hutchison Medipharma Enterprises Limited | Andrographis paniculata extract |
US8557302B2 (en) | 2007-11-02 | 2013-10-15 | Nutrition Science Partners Limited | Andrographis paniculata extract |
US8557308B2 (en) | 2007-11-02 | 2013-10-15 | Nutrition Science Partners Limited | Andrographis paniculata extract |
Also Published As
Publication number | Publication date |
---|---|
KR20150047645A (en) | 2015-05-04 |
CA2564637A1 (en) | 2005-11-10 |
WO2005104722A3 (en) | 2006-03-02 |
KR101531116B1 (en) | 2015-06-23 |
KR20070033982A (en) | 2007-03-27 |
PT1747008E (en) | 2015-03-31 |
WO2005104722A2 (en) | 2005-11-10 |
US7341748B2 (en) | 2008-03-11 |
KR101536892B1 (en) | 2015-07-14 |
RU2383353C2 (en) | 2010-03-10 |
KR20130012979A (en) | 2013-02-05 |
AU2005237550A1 (en) | 2005-11-10 |
EP1747008A2 (en) | 2007-01-31 |
TW200538144A (en) | 2005-12-01 |
AU2005237550B2 (en) | 2010-09-23 |
RU2006141834A (en) | 2008-06-10 |
HUE025117T2 (en) | 2016-02-29 |
US20060246156A1 (en) | 2006-11-02 |
PL1747008T3 (en) | 2015-10-30 |
CA2564637C (en) | 2013-09-10 |
USRE42718E1 (en) | 2011-09-20 |
JP2007535542A (en) | 2007-12-06 |
EP1747008B1 (en) | 2015-01-14 |
KR101534844B1 (en) | 2015-07-07 |
ES2534594T3 (en) | 2015-04-24 |
JP5221128B2 (en) | 2013-06-26 |
DK1747008T3 (en) | 2015-03-30 |
TWI373340B (en) | 2012-10-01 |
EP1747008A4 (en) | 2009-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE43423E1 (en) | Crude extracts from Andrographis paniculata | |
US7625945B2 (en) | Andrographolide and analogues as inhibitors of TNFα and IL-1β expression | |
US8557302B2 (en) | Andrographis paniculata extract | |
US20050124684A1 (en) | 5-(hydroxymethyl) furfural and derivatives as inhibitors of TNFalpha and IL-1beta production | |
JP2016523849A (en) | Combination therapy for prostate cancer using plant composition and docetaxel | |
US20060110467A1 (en) | Cancer chemotherapy | |
US20050148616A1 (en) | Inhibitor of TNF-alpha and IL-1beta production | |
KR100889169B1 (en) | Antagonistic pharmaceutical composition for neurokinin-1 receptor | |
KR0143719B1 (en) | Polyoxypregnane Glycosides with Multi-drug Resistance Regulation of Cancer Cells Extracted from Baek Ha Shou | |
KR20090087684A (en) | Composition for preventing or treating a disease mediated by overexpression of heat shock protein 27 | |
KR20200029702A (en) | Pharmaceutical composition including abeliophyllum distichum extract for preventing or treating liver injury | |
KR20220041870A (en) | bioactive phytochemicals | |
KR20160065336A (en) | Composition comprising petatewalid B for preventing or treating allergy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
CC | Certificate of correction | ||
CC | Certificate of correction | ||
AS | Assignment |
Owner name: NUTRITION SCIENCE PARTNERS LIMITED, HONG KONG Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HUTCHISON MEDIPHARMA ENTERPRISES LIMITED;REEL/FRAME:030658/0421 Effective date: 20130529 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 12 |